Abstract
Although not frequently mutated in prostate cancer Ras isoforms play a pivotal role in multiple pathways that have been implicated in prostate cancer progression to androgen independence. These have included growth factor and cytokine induced activation of the androgen receptor and its coregulators by post translational modification. Current evidence suggests that Ras is also required for androgen receptor activation in hormone sensitive cells. More recently Ras has been shown to work synergistically with other pathways to promote prostate tumorigenesis. We review the multiple lines of evidence implicating Ras as therapeutic target in androgen dependent and independent prostate cancer.
Keywords: Androgen receptor, growth factor, signal transduction, anti-androgen.
Current Cancer Drug Targets
Title:RAS Pathways in Prostate Cancer - Mediators of Hormone Resistance?
Volume: 10 Issue: 8
Author(s): H. C. Whitaker and D. E. Neal
Affiliation:
Keywords: Androgen receptor, growth factor, signal transduction, anti-androgen.
Abstract: Although not frequently mutated in prostate cancer Ras isoforms play a pivotal role in multiple pathways that have been implicated in prostate cancer progression to androgen independence. These have included growth factor and cytokine induced activation of the androgen receptor and its coregulators by post translational modification. Current evidence suggests that Ras is also required for androgen receptor activation in hormone sensitive cells. More recently Ras has been shown to work synergistically with other pathways to promote prostate tumorigenesis. We review the multiple lines of evidence implicating Ras as therapeutic target in androgen dependent and independent prostate cancer.
Export Options
About this article
Cite this article as:
C. Whitaker H. and E. Neal D., RAS Pathways in Prostate Cancer - Mediators of Hormone Resistance?, Current Cancer Drug Targets 2010; 10 (8) . https://dx.doi.org/10.2174/156800910793358005
DOI https://dx.doi.org/10.2174/156800910793358005 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanistic Overview of Immune Modulatory Effects of Environmental Toxicants
Inflammation & Allergy - Drug Targets (Discontinued) Theranostics of Metastatic Prostate Cancer Applying <sup>64</sup>Cu/<sup>18</sup>F/<sup>68</sup>Ga PSMA PET-CT and <sup>177</sup>Lu Radiopharmaceuticals
Current Radiopharmaceuticals Genomic and Cellular Pathology of Lung Cancer
Current Respiratory Medicine Reviews Molecular Signatures of Biomarkers in Cancer Development, Diagn osis, and its Prognostic Accuracy
Current Biomarkers (Discontinued) Do We have the Evidence to Repurpose Levamisole for Treatment of COVID 19?
Current Drug Therapy Ecosustainable Development of Novel Bio-inorganic Hybrid Materials as UV Protection Systems for Potential Cosmetic Applications
Current Pharmaceutical Biotechnology 2-Arylbenzothiazole as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Natural Products, Synthetic and Non-Nucleoside Compounds as Inhibitors of Enzymes Related to DNA: Update 2013
Current Enzyme Inhibition Anticancer Drug Discovery from the Marine Environment
Recent Patents on Anti-Cancer Drug Discovery Genistein: A Boon for Mitigating Ischemic Stroke
Current Topics in Medicinal Chemistry γ δ T Cell Modulation in Anticancer Treatment
Current Cancer Drug Targets Translational Peptide-associated Nanosystems: Promising Role as Cancer Vaccines
Current Topics in Medicinal Chemistry Review: The Role of MOP and DOP Receptors in Treatment of Diarrheapredominant Irritable Bowel Syndrome
Mini-Reviews in Medicinal Chemistry Role of Nuclear Steroid Receptors in Apoptosis
Current Medicinal Chemistry HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Application of Optimization Technique to Develop Nano-Based Carrier of Nigella Sativa Essential Oil: Characterization and Assessment
Recent Patents on Drug Delivery & Formulation Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Facile Synthesis of Anticancer Drug NCX 4040 in Mild Conditions
Letters in Organic Chemistry Targeted Drug Delivery and Imaging Using Mobile Milli/Microrobots: A Promising Future Towards Theranostic Pharmaceutical Design
Current Pharmaceutical Design Recent Patents on the Baculovirus Systems
Recent Patents on Biotechnology